Alexander Stephen P.H., Benson Helen E., Faccenda Elena, Pawson Adam J., Sharman Joanna L., Spedding Michael, Peters John A., Harmar Anthony J. (2013): The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. British Journal of Pharmacology, 170, 1459-1581  https://doi.org/10.1111/bph.12445Appendino Giovanni, Gibbons Simon, Giana Anna, Pagani Alberto, Grassi Gianpaolo, Stavri Michael, Smith Eileen, Rahman M. Mukhlesur (2008): Antibacterial Cannabinoids from Cannabis sativa : A Structure−Activity Study. Journal of Natural Products, 71, 1427-1430  https://doi.org/10.1021/np8002673Batkai S. (2004): Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension. Circulation, 110, 1996-2002  https://doi.org/10.1161/01.CIR.0000143230.23252.D2Battista Natalia, Di Tommaso Monia, Bari Monica, Maccarrone Mauro (2012): The endocannabinoid system: an overview. Frontiers in Behavioral Neuroscience, 6, -  https://doi.org/10.3389/fnbeh.2012.00009BISOGNO Tiziana, MELCK Dominique, BOBROV Mikhail Yu., GRETSKAYA Natalia M., BEZUGLOV Vladimir V., DE PETROCELLIS Luciano, DI MARZO Vincenzo (): N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal, 351, 817-824  https://doi.org/10.1042/bj3510817Blake D. R. (2006): Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology, 45, 50-52  https://doi.org/10.1093/rheumatology/kei183 Caffarel MM, Andradas C, Perez-Gomez E, Guzman M, Sanchez C (2012): Cannabinoids: A new hope for breast cancer therapy? Cancer Treatment Reviews 38, 911–918.Castillo Pablo E., Younts Thomas J., Chávez Andrés E., Hashimotodani Yuki (2012): Endocannabinoid Signaling and Synaptic Function. Neuron, 76, 70-81  https://doi.org/10.1016/j.neuron.2012.09.020Cerrato S., Brazis P., della Valle M.F., Miolo A., Puigdemont A. (2010): Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFα release from canine skin mast cells. Veterinary Immunology and Immunopathology, 133, 9-15  https://doi.org/10.1016/j.vetimm.2009.06.011Cerrato Santiago, Brazis Pilar, della Valle Maria Federica, Miolo Alda, Petrosino Stefania, Marzo Vincenzo Di, Puigdemont Anna (2012): Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. The Veterinary Journal, 191, 377-382  https://doi.org/10.1016/j.tvjl.2011.04.002Chambers Adam P, Koopmans Henry S, Pittman Quentin J, Sharkey Keith A (2006): AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion. British Journal of Pharmacology, 147, 109-116  https://doi.org/10.1038/sj.bjp.0706439Chien Fred Y. (2003): Effect of WIN 55212-2, a Cannabinoid Receptor Agonist, on Aqueous Humor Dynamics in Monkeys. Archives of Ophthalmology, 121, 87-  https://doi.org/10.1001/archopht.121.1.87Contassot Emmanuel, Wilmotte Rick, Tenan Mirna, Belkouch Marie-Claude, Schnüriger Valérie, De Tribolet Nicolas, Bourkhardt Karim, Dietrich Pierre-Yves (): Arachidonylethanolamide Induces Apoptosis of Human Glioma Cells through Vanilloid Receptor-1. Journal of Neuropathology & Experimental Neurology, 63, 956-963  https://doi.org/10.1093/jnen/63.9.956Croxford J Ludovic (2003): Therapeutic Potential of Cannabinoids in CNS Disease. CNS Drugs, 17, 179-202  https://doi.org/10.2165/00023210-200317030-00004 Croxford JL, Yamamura T (2005): Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases? Journal of Neuroimmunology 166, 3–18. Darmani NA (2001a): Δ9-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24, 198–203. Darmani NA (2001b): Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacology Biochemistry and Behavior 69, 239–249.RODRIGUEZ de FONSECA F. (2004): THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY. Alcohol and Alcoholism, 40, 2-14  https://doi.org/10.1093/alcalc/agh110Devane W., Hanus L, Breuer A, Pertwee R., Stevenson L., Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992): Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949  https://doi.org/10.1126/science.1470919Di Filippo C. (2003): Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. Journal of Leukocyte Biology, 75, 453-459  https://doi.org/10.1189/jlb.0703303El-Remessy Azza B., Al-Shabrawey Mohamed, Khalifa Yousuf, Tsai Nai-Tse, Caldwell Ruth B., Liou Gregory I. (2006): Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes. The American Journal of Pathology, 168, 235-244  https://doi.org/10.2353/ajpath.2006.050500Fattore L., Fadda P., Spano M.S., Pistis M., Fratta W. (2008): Neurobiological mechanisms of cannabinoid addiction. Molecular and Cellular Endocrinology, 286, S97-S107  https://doi.org/10.1016/j.mce.2008.02.006 Figueiredo AS, Garcia-Crescioni HJ, Bulla SC, Ross MK, McIntosh C, Lunsford K, Bulla C (2013): Suppression of vascular endothelial growth factor expression by cannabinoids in a canine osteosarcoma cell line. Veterinary Medicine: Research and Reports 4, 31–34.Fisar Zdenek (2009): Phytocannabinoids and Endocannabinoids. Current Drug Abuse Reviewse, 2, 51-75  https://doi.org/10.2174/1874473710902010051Fischer Kristin M., Ward Daniel A., Hendrix Diane V. H. (2013): Effects of a topically applied 2% delta-9-tetrahydrocannabinol ophthalmic solution on intraocular pressure and aqueous humor flow rate in clinically normal dogs. American Journal of Veterinary Research, 74, 275-280  https://doi.org/10.2460/ajvr.74.2.275Fitzgerald Kevin T., Bronstein Alvin C., Newquist Kristin L. (2013): Marijuana Poisoning. Topics in Companion Animal Medicine, 28, 8-12  https://doi.org/10.1053/j.tcam.2013.03.004Gaffuri Anne-Lise, Ladarre Delphine, Lenkei Zsolt (2012): Type-1 Cannabinoid Receptor Signaling in Neuronal Development. Pharmacology, 90, 19-39  https://doi.org/10.1159/000339075Galiegue Sylvaine, Mary Sophie, Marchand Jean, Dussossoy Danielle, Carriere Dominique, Carayon Pierre, Bouaboula Monsif, Shire David, Fur Gerard, Casellas Pierre (1995): Expression of Central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations. European Journal of Biochemistry, 232, 54-61  https://doi.org/10.1111/j.1432-1033.1995.tb20780.xGaoni Y., Mechoulam R. (1964): Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. Journal of the American Chemical Society, 86, 1646-1647  https://doi.org/10.1021/ja01062a046Giannini L., Nistri S., Mastroianni R., Cinci L., Vannacci A., Mariottini C., Passani M. B., Mannaioni P. F., Bani D., Masini E. (2008): Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs. Journal of Cellular and Molecular Medicine, 12, 2381-2394  https://doi.org/10.1111/j.1582-4934.2008.00258.xGirling S. J., Fraser M. A. (2011): Cannabis intoxication in three Green iguanas (Iguana iguana). Journal of Small Animal Practice, 52, 113-116  https://doi.org/10.1111/j.1748-5827.2010.01017.xGrimaldi Claudia, Pisanti Simona, Laezza Chiara, Malfitano Anna Maria, Santoro Antonietta, Vitale Mario, Caruso Maria Gabriella, Notarnicola Maria, Iacuzzo Irma, Portella Giuseppe, Di Marzo Vincenzo, Bifulco Maurizio (2006): Anandamide inhibits adhesion and migration of breast cancer cells. Experimental Cell Research, 312, 363-373  https://doi.org/10.1016/j.yexcr.2005.10.024Gorji Ali, Ghadiri Maryam Khaleghi (2002): History of headache in medieval Persian medicine. The Lancet Neurology, 1, 510-515  https://doi.org/10.1016/S1474-4422(02)00226-0 Grotenhermen F (2006): Cannabinoids and the endocannabinoid system. Cannabinoids 1, 10–14. Grotenhermen F, Muller-Vahl K (2012): The therapeutic potential of cannabis and cannabinoids. Deutsches Arzteblatt International 109, 495–501.Guzmán Manuel (2003): Cannabinoids: potential anticancer agents. Nature Reviews Cancer, 3, 745-755  https://doi.org/10.1038/nrc1188Han Sangdon, Thatte Jayant, Buzard Daniel J., Jones Robert M. (2013): Therapeutic Utility of Cannabinoid Receptor Type 2 (CB ₂ ) Selective Agonists. Journal of Medicinal Chemistry, 56, 8224-8256  https://doi.org/10.1021/jm4005626Hanus L., Breuer A., Tchilibon S., Shiloah S., Goldenberg D., Horowitz M., Pertwee R. G., Ross R. A., Mechoulam R., Fride E. (1999): HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proceedings of the National Academy of Sciences, 96, 14228-14233  https://doi.org/10.1073/pnas.96.25.14228Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D. E., Kustanovich I., Mechoulam R. (2001): 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences, 98, 3662-3665  https://doi.org/10.1073/pnas.061029898Hayakawa Kazuhide, Mishima Kenichi, Fujiwara Michihiro (2010): Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke. Pharmaceuticals, 3, 2197-2212  https://doi.org/10.3390/ph3072197Heifets Boris D., Castillo Pablo E. (2009): Endocannabinoid Signaling and Long-Term Synaptic Plasticity. Annual Review of Physiology, 71, 283-306  https://doi.org/10.1146/annurev.physiol.010908.163149Hildebrandt Audrey L., Kelly-Sullivan Dawn M., Black Shawn C. (2003): Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. European Journal of Pharmacology, 462, 125-132  https://doi.org/10.1016/S0014-2999(03)01343-8Hill Andrew J., Williams Claire M., Whalley Benjamin J., Stephens Gary J. (2012): Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics, 133, 79-97  https://doi.org/10.1016/j.pharmthera.2011.09.002Izzo Angelo A., Borrelli Francesca, Capasso Raffaele, Di Marzo Vincenzo, Mechoulam Raphael (2009): Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences, 30, 515-527  https://doi.org/10.1016/j.tips.2009.07.006Jan Tong-Rong, Farraj Aimen K, Harkema Jack R, Kaminski Norbert E (2003): Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice ☆. Toxicology and Applied Pharmacology, 188, 24-35  https://doi.org/10.1016/S0041-008X(03)00010-3 Jones RT (2002): Cardiovascular system effects of marijuana. The Journal of Clinical Pharmacology 42, 58S–63S.Kalant Harold (2001): Medicinal Use of Cannabis: History and Current Status. Pain Research and Management, 6, 80-91  https://doi.org/10.1155/2001/469629Karst Matthias, Wippermann Sonja, Ahrens Jörg (2010): Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity. Drugs, 70, 2409-2438  https://doi.org/10.2165/11585260-000000000-00000M. Keppel Hesselink Jan (2012): New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide. The Open Pain Journal, 5, 12-23  https://doi.org/10.2174/1876386301205010012Kluger Benzi, Triolo Piera, Jones Wallace, Jankovic Joseph (2015): The therapeutic potential of cannabinoids for movement disorders. Movement Disorders, 30, 313-327  https://doi.org/10.1002/mds.26142Kucerova Jana, Tabiova Katarina, Drago Filippo, Micale Vincenzo (2014): Therapeutic Potential of Cannabinoids in Schizophrenia. Recent Patents on CNS Drug Discovery, 9, 13-25  https://doi.org/10.2174/1574889809666140307115532 Landa L, Slais K, Machalova A, Sulcova A (2014a): The effect of cannabinoid CB1 receptor agonist arachidonylcyclopropylamide (ACPA) on behavioural sensitisation to methamphetamine in mice. Veterinarni Medicina 59, 88–94. Landa L, Slais K, Machalova A, Sulcova A (2014b): Interaction of CB1 receptor agonist arachidonylcyclopropylamide with behavioural sensitisation to morphine in mice. Veterinarni Medicina 59, 307–314.Lax Pedro, Esquiva Gema, Altavilla Cesare, Cuenca Nicolás (2014): Neuroprotective effects of the cannabinoid agonist HU210 on retinal degeneration. Experimental Eye Research, 120, 175-185  https://doi.org/10.1016/j.exer.2014.01.019Looney Andrea (2010): Oncology Pain in Veterinary Patients. Topics in Companion Animal Medicine, 25, 32-44  https://doi.org/10.1053/j.tcam.2009.10.008LoVerme Jesse, La Rana Giovanna, Russo Roberto, Calignano Antonio, Piomelli Daniele (2005): The search for the palmitoylethanolamide receptor. Life Sciences, 77, 1685-1698  https://doi.org/10.1016/j.lfs.2005.05.012Luongo Livio, Guida Francesca, Boccella Serena, Bellini Giulia, Gatta Luisa, Rossi Francesca, de Novellis Vito, Maione Sabatino (2013): Palmitoylethanolamide Reduces Formalin-Induced Neuropathic-Like Behaviour Through Spinal Glial/Microglial Phenotypical Changes in Mice. CNS & Neurological Disorders - Drug Targets, 12, 45-54  https://doi.org/10.2174/1871527311312010009Lynch Mary E., Campbell Fiona (2011): Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology, 72, 735-744  https://doi.org/10.1111/j.1365-2125.2011.03970.xLynch M. E., Ware Mark A. (2015): Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials. Journal of Neuroimmune Pharmacology, 10, 293-301  https://doi.org/10.1007/s11481-015-9600-6Lynch Mary E., Cesar-Rittenberg Paula, Hohmann Andrea G. (2014): A Double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension Using an Oral Mucosal Cannabinoid Extract for Treatment of Chemotherapy-Induced Neuropathic Pain. Journal of Pain and Symptom Management, 47, 166-173  https://doi.org/10.1016/j.jpainsymman.2013.02.018Maione Sabatino, Costa Barbara, Di Marzo Vincenzo (2013): Endocannabinoids: A unique opportunity to develop multitarget analgesics. PAIN®, 154, S87-S93  https://doi.org/10.1016/j.pain.2013.03.023Massi Paola, Solinas Marta, Cinquina Valentina, Parolaro Daniela (2013): Cannabidiol as potential anticancer drug. British Journal of Clinical Pharmacology, 75, 303-312  https://doi.org/10.1111/j.1365-2125.2012.04298.xMatsuda Lisa A., Lolait Stephen J., Brownstein Michael J., Young Alice C., Bonner Tom I. (1990): Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564  https://doi.org/10.1038/346561a0 McCarthy LE, Borison HL (1981): Antiemetic activity of N-methyllevonantradol and nabilone in cisplatin-treated cats. Journal of Clinical Pharmacology 21, 30S–37S.Mechoulam Raphael (2005): Plant cannabinoids: a neglected pharmacological treasure trove. British Journal of Pharmacology, 146, 913-915  https://doi.org/10.1038/sj.bjp.0706415Mechoulam Raphael, Fride Ester, Di Marzo Vincenzo (1998): Endocannabinoids. European Journal of Pharmacology, 359, 1-18  https://doi.org/10.1016/S0014-2999(98)00649-9Mechoulam Raphael, Hanuš Lumír O., Pertwee Roger, Howlett Allyn C. (): Early phytocannabinoid chemistry to endocannabinoids and beyond. Nature Reviews Neuroscience, 15, 757-764  https://doi.org/10.1038/nrn3811Mendizábal V E, Adler-Graschinsky E (2007): Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. British Journal of Pharmacology, 151, 427-440  https://doi.org/10.1038/sj.bjp.0707261Meola Stacy D., Tearney Caitlin C., Haas Sharlee A., Hackett Timothy B., Mazzaferro Elisa M. (2012): Evaluation of trends in marijuana toxicosis in dogs living in a state with legalized medical marijuana: 125 dogs (2005-2010). Journal of Veterinary Emergency and Critical Care, 22, 690-696  https://doi.org/10.1111/j.1476-4431.2012.00818.xMiller L. K., Devi L. A. (): The Highs and Lows of Cannabinoid Receptor Expression in Disease: Mechanisms and Their Therapeutic Implications. Pharmacological Reviews, 63, 461-470  https://doi.org/10.1124/pr.110.003491Muccioli Giulio G. (2010): Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discovery Today, 15, 474-483  https://doi.org/10.1016/j.drudis.2010.03.007Mukhopadhyay Partha, Bátkai Sándor, Rajesh Mohanraj, Czifra Nora, Harvey-White Judith, Haskó György, Zsengeller Zsuzsanna, Gerard Norma P., Liaudet Lucas, Kunos George, Pacher Pál (2007): Pharmacological Inhibition of CB1 Cannabinoid Receptor Protects Against Doxorubicin-Induced Cardiotoxicity. Journal of the American College of Cardiology, 50, 528-536  https://doi.org/10.1016/j.jacc.2007.03.057Munro Sean, Thomas Kerrie L., Abu-Shaar Muna (1993): Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65  https://doi.org/10.1038/365061a0Nagarkatti Prakash, Pandey Rupal, Rieder Sadiye Amcaoglu, Hegde Venkatesh L, Nagarkatti Mitzi (2009): Cannabinoids as novel anti-inflammatory drugs. Future Medicinal Chemistry, 1, 1333-1349  https://doi.org/10.4155/fmc.09.93 Nolen RS (2013): With pet owners already using the drug as medicine, veterinarians need to join the debate. Journal of the American Veterinary Medical Association 242, 1604–1609.Pacher P. (2006): The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews, 58, 389-462  https://doi.org/10.1124/pr.58.3.2Parker Linda A., Kwiatkowska Magdalena, Burton Page, Mechoulam Raphael (2004): Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology, 171, 156-161  https://doi.org/10.1007/s00213-003-1571-2Pascual David, Goicoechea Carlos, Suardíaz Margarita, Martín María Isabel (2005): A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain, 118, 23-34  https://doi.org/10.1016/j.pain.2005.07.008Pate David W., Järvinen Kristiina, Urtti Arto, Mahadevan Vaidyanath, Järvinen Tomi (1998): Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sciences, 63, 2181-2188  https://doi.org/10.1016/S0024-3205(98)00499-8Pertwee Roger G. (1997): Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology & Therapeutics, 74, 129-180  https://doi.org/10.1016/S0163-7258(97)82001-3Pertwee Roger G. (2005): The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. The AAPS Journal, 7, E625-E654  https://doi.org/10.1208/aapsj070364Pertwee Roger G (2009): Emerging strategies for exploiting cannabinoid receptor agonists as medicines. British Journal of Pharmacology, 156, 397-411  https://doi.org/10.1111/j.1476-5381.2008.00048.xPertwee Roger G. (2014): Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proceedings of the Nutrition Society, 73, 96-105  https://doi.org/10.1017/S0029665113003649Porcella Anna, Maxia Chiara, Gessa Gian Luigi, Pani Luca (2001): The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. European Journal of Neuroscience, 13, 409-412  https://doi.org/10.1046/j.0953-816X.2000.01401.xPorter A. C. (): Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor. Journal of Pharmacology and Experimental Therapeutics, 301, 1020-1024  https://doi.org/10.1124/jpet.301.3.1020 Presley BC, Jansen-Varnum SA, Logan BK (2013): Analysis of synthetic cannabinoids in botanical material: A review of analytical methods and findings. Forensic Science Review 25, 27–46.Re G., Barbero R., Miolo A., Di Marzo V. (2007): Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. The Veterinary Journal, 173, 21-30  https://doi.org/10.1016/j.tvjl.2005.10.003ROBSON P. (): Therapeutic aspects of cannabis and cannabinoids. The British Journal of Psychiatry, 178, 107-115  https://doi.org/10.1192/bjp.178.2.107Rog D. J., Nurmikko T. J., Friede T., Young C. A. (): Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 65, 812-819  https://doi.org/10.1212/01.wnl.0000176753.45410.8bRoss Ruth A (2003): Anandamide and vanilloid TRPV1 receptors. British Journal of Pharmacology, 140, 790-801  https://doi.org/10.1038/sj.bjp.0705467Russo Ethan (2008): Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management, Volume 4, 245-259  https://doi.org/10.2147/TCRM.S1928Sarfaraz S., Adhami V. M., Syed D. N., Afaq F., Mukhtar H. (2008): Cannabinoids for Cancer Treatment: Progress and Promise. Cancer Research, 68, 339-342  https://doi.org/10.1158/0008-5472.CAN-07-2785Scarampella F., Abramo F., Noli C. (2001): Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Veterinary Dermatology, 12, 29-39  https://doi.org/10.1046/j.1365-3164.2001.00214.xScheen André J., Paquot Nicolas (2009): Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Practice & Research Clinical Endocrinology & Metabolism, 23, 103-116  https://doi.org/10.1016/j.beem.2008.09.001Serpell M., Ratcliffe S., Hovorka J., Schofield M., Taylor L., Lauder H., Ehler E. (2014): A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain, 18, 999-1012  https://doi.org/10.1002/j.1532-2149.2013.00445.xSlais K., Landa L., Sulcova A. (2003): P.5.023 The effects of cannabinoid CB1 receptor antagonist AM 251 on locomotor/exploratory behaviour and body weight in mice. European Neuropsychopharmacology, 13, S417-  https://doi.org/10.1016/S0924-977X(03)92272-3Slavic Svetlana, Lauer Dilyara, Sommerfeld Manuela, Kemnitz Ulrich Rudolf, Grzesiak Aleksandra, Trappiel Manuela, Thöne-Reineke Christa, Baulmann Johannes, Paulis Ludovit, Kappert Kai, Kintscher Ulrich, Unger Thomas, Kaschina Elena (2013): Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. Journal of Molecular Medicine, 91, 811-823  https://doi.org/10.1007/s00109-013-1034-0 Song ZH, Slowey CA (2000): Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. Journal of Pharmacology and Experimental Therapeutics 292, 136–139. Stanley CP, Hind WH, O’Sullivan SE (2013): Is the cardiovascular system a therapeutic target for cannabidiol? British Journal of Clinical Pharmacology 75, 313–322.Steffens Sabine, Pacher Pál (2012): Targeting cannabinoid receptor CB2 in cardiovascular disorders: promises and controversies. British Journal of Pharmacology, 167, 313-323  https://doi.org/10.1111/j.1476-5381.2012.02042.xSteffens Sabine, Veillard Niels R., Arnaud Claire, Pelli Graziano, Burger Fabienne, Staub Christian, Zimmer Andreas, Frossard Jean-Louis, Mach François (2005): Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature, 434, 782-786  https://doi.org/10.1038/nature03389SVIZENSKA I, DUBOVY P, SULCOVA A (2008): Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures — A short review. Pharmacology Biochemistry and Behavior, 90, 501-511  https://doi.org/10.1016/j.pbb.2008.05.010Tallett Amy J., Blundell John E., Rodgers John R. (2007): Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation. Behavioural Pharmacology, 18, 591-600  https://doi.org/10.1097/FBP.0b013e3282eff0a9 Unschuld PU (1986): Medicine in China. A History of Pharmaceutics. University of California Press, Berkeley and Los Angele. 167 pp.Van Sickle Marja D., Oland Lorraine D., Mackie Ken, Davison Joseph S., Sharkey Keith A. (): Δ ⁹ -Tetrahydrocannabinol selectively acts on CB ₁ receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. American Journal of Physiology - Gastrointestinal and Liver Physiology, 285, G566-G576  https://doi.org/10.1152/ajpgi.00113.2003Van Sickle M. D. (2005): Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors. Science, 310, 329-332  https://doi.org/10.1126/science.1115740Velasco Guillermo, Sánchez Cristina, Guzmán Manuel (): Towards the use of cannabinoids as antitumour agents. Nature Reviews Cancer, 12, 436-444  https://doi.org/10.1038/nrc3247Weiss L., Zeira M., Reich S., Har-Noy M., Mechoulam R., Slavin S., Gallily R. (2006): Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity, 39, 143-151  https://doi.org/10.1080/08916930500356674Weiss Lola, Zeira Michael, Reich Shoshana, Slavin Shimon, Raz Itamar, Mechoulam Raphael, Gallily Ruth (2008): Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology, 54, 244-249  https://doi.org/10.1016/j.neuropharm.2007.06.029Xiong W., Cui T., Cheng K., Yang F., Chen S.-R., Willenbring D., Guan Y., Pan H.-L., Ren K., Xu Y., Zhang L. (): Cannabinoids suppress inflammatory and neuropathic pain by targeting  3 glycine receptors. Journal of Experimental Medicine, 209, 1121-1134  https://doi.org/10.1084/jem.20120242Zuardi Antonio Waldo (2006): History of cannabis as a medicine: a review. Revista Brasileira de Psiquiatria, 28, 153-157  https://doi.org/10.1590/S1516-44462006000200015 Zubrzycki M, Liebold A, Janecka A, Zubrzycka M (2014): A new face of endocannabinoids in pharmacotherapy. Part I: Protective role of endocannabinoids in hypertension and myocardial infarction. Journal of Physiology and Pharmacology 65, 171–181.Alexander Stephen P.H., Benson Helen E., Faccenda Elena, Pawson Adam J., Sharman Joanna L., Spedding Michael, Peters John A., Harmar Anthony J. (2013): The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. British Journal of Pharmacology, 170, 1459-1581  https://doi.org/10.1111/bph.12445Appendino Giovanni, Gibbons Simon, Giana Anna, Pagani Alberto, Grassi Gianpaolo, Stavri Michael, Smith Eileen, Rahman M. Mukhlesur (2008): Antibacterial Cannabinoids from Cannabis sativa : A Structure−Activity Study. Journal of Natural Products, 71, 1427-1430  https://doi.org/10.1021/np8002673Batkai S. (2004): Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension. Circulation, 110, 1996-2002  https://doi.org/10.1161/01.CIR.0000143230.23252.D2Battista Natalia, Di Tommaso Monia, Bari Monica, Maccarrone Mauro (2012): The endocannabinoid system: an overview. Frontiers in Behavioral Neuroscience, 6, -  https://doi.org/10.3389/fnbeh.2012.00009BISOGNO Tiziana, MELCK Dominique, BOBROV Mikhail Yu., GRETSKAYA Natalia M., BEZUGLOV Vladimir V., DE PETROCELLIS Luciano, DI MARZO Vincenzo (): N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal, 351, 817-824  https://doi.org/10.1042/bj3510817Blake D. R. (2006): Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology, 45, 50-52  https://doi.org/10.1093/rheumatology/kei183 Caffarel MM, Andradas C, Perez-Gomez E, Guzman M, Sanchez C (2012): Cannabinoids: A new hope for breast cancer therapy? Cancer Treatment Reviews 38, 911–918.Castillo Pablo E., Younts Thomas J., Chávez Andrés E., Hashimotodani Yuki (2012): Endocannabinoid Signaling and Synaptic Function. Neuron, 76, 70-81  https://doi.org/10.1016/j.neuron.2012.09.020Cerrato S., Brazis P., della Valle M.F., Miolo A., Puigdemont A. (2010): Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFα release from canine skin mast cells. Veterinary Immunology and Immunopathology, 133, 9-15  https://doi.org/10.1016/j.vetimm.2009.06.011Cerrato Santiago, Brazis Pilar, della Valle Maria Federica, Miolo Alda, Petrosino Stefania, Marzo Vincenzo Di, Puigdemont Anna (2012): Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. The Veterinary Journal, 191, 377-382  https://doi.org/10.1016/j.tvjl.2011.04.002Chambers Adam P, Koopmans Henry S, Pittman Quentin J, Sharkey Keith A (2006): AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion. British Journal of Pharmacology, 147, 109-116  https://doi.org/10.1038/sj.bjp.0706439Chien Fred Y. (2003): Effect of WIN 55212-2, a Cannabinoid Receptor Agonist, on Aqueous Humor Dynamics in Monkeys. Archives of Ophthalmology, 121, 87-  https://doi.org/10.1001/archopht.121.1.87Contassot Emmanuel, Wilmotte Rick, Tenan Mirna, Belkouch Marie-Claude, Schnüriger Valérie, De Tribolet Nicolas, Bourkhardt Karim, Dietrich Pierre-Yves (): Arachidonylethanolamide Induces Apoptosis of Human Glioma Cells through Vanilloid Receptor-1. Journal of Neuropathology & Experimental Neurology, 63, 956-963  https://doi.org/10.1093/jnen/63.9.956Croxford J Ludovic (2003): Therapeutic Potential of Cannabinoids in CNS Disease. CNS Drugs, 17, 179-202  https://doi.org/10.2165/00023210-200317030-00004 Croxford JL, Yamamura T (2005): Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases? Journal of Neuroimmunology 166, 3–18. Darmani NA (2001a): Δ9-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24, 198–203. Darmani NA (2001b): Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacology Biochemistry and Behavior 69, 239–249.RODRIGUEZ de FONSECA F. (2004): THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY. Alcohol and Alcoholism, 40, 2-14  https://doi.org/10.1093/alcalc/agh110Devane W., Hanus L, Breuer A, Pertwee R., Stevenson L., Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992): Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949  https://doi.org/10.1126/science.1470919Di Filippo C. (2003): Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. Journal of Leukocyte Biology, 75, 453-459  https://doi.org/10.1189/jlb.0703303El-Remessy Azza B., Al-Shabrawey Mohamed, Khalifa Yousuf, Tsai Nai-Tse, Caldwell Ruth B., Liou Gregory I. (2006): Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes. The American Journal of Pathology, 168, 235-244  https://doi.org/10.2353/ajpath.2006.050500Fattore L., Fadda P., Spano M.S., Pistis M., Fratta W. (2008): Neurobiological mechanisms of cannabinoid addiction. Molecular and Cellular Endocrinology, 286, S97-S107  https://doi.org/10.1016/j.mce.2008.02.006 Figueiredo AS, Garcia-Crescioni HJ, Bulla SC, Ross MK, McIntosh C, Lunsford K, Bulla C (2013): Suppression of vascular endothelial growth factor expression by cannabinoids in a canine osteosarcoma cell line. Veterinary Medicine: Research and Reports 4, 31–34.Fisar Zdenek (2009): Phytocannabinoids and Endocannabinoids. Current Drug Abuse Reviewse, 2, 51-75  https://doi.org/10.2174/1874473710902010051Fischer Kristin M., Ward Daniel A., Hendrix Diane V. H. (2013): Effects of a topically applied 2% delta-9-tetrahydrocannabinol ophthalmic solution on intraocular pressure and aqueous humor flow rate in clinically normal dogs. American Journal of Veterinary Research, 74, 275-280  https://doi.org/10.2460/ajvr.74.2.275Fitzgerald Kevin T., Bronstein Alvin C., Newquist Kristin L. (2013): Marijuana Poisoning. Topics in Companion Animal Medicine, 28, 8-12  https://doi.org/10.1053/j.tcam.2013.03.004Gaffuri Anne-Lise, Ladarre Delphine, Lenkei Zsolt (2012): Type-1 Cannabinoid Receptor Signaling in Neuronal Development. Pharmacology, 90, 19-39  https://doi.org/10.1159/000339075Galiegue Sylvaine, Mary Sophie, Marchand Jean, Dussossoy Danielle, Carriere Dominique, Carayon Pierre, Bouaboula Monsif, Shire David, Fur Gerard, Casellas Pierre (1995): Expression of Central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations. European Journal of Biochemistry, 232, 54-61  https://doi.org/10.1111/j.1432-1033.1995.tb20780.xGaoni Y., Mechoulam R. (1964): Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. Journal of the American Chemical Society, 86, 1646-1647  https://doi.org/10.1021/ja01062a046Giannini L., Nistri S., Mastroianni R., Cinci L., Vannacci A., Mariottini C., Passani M. B., Mannaioni P. F., Bani D., Masini E. (2008): Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs. Journal of Cellular and Molecular Medicine, 12, 2381-2394  https://doi.org/10.1111/j.1582-4934.2008.00258.xGirling S. J., Fraser M. A. (2011): Cannabis intoxication in three Green iguanas (Iguana iguana). Journal of Small Animal Practice, 52, 113-116  https://doi.org/10.1111/j.1748-5827.2010.01017.xGrimaldi Claudia, Pisanti Simona, Laezza Chiara, Malfitano Anna Maria, Santoro Antonietta, Vitale Mario, Caruso Maria Gabriella, Notarnicola Maria, Iacuzzo Irma, Portella Giuseppe, Di Marzo Vincenzo, Bifulco Maurizio (2006): Anandamide inhibits adhesion and migration of breast cancer cells. Experimental Cell Research, 312, 363-373  https://doi.org/10.1016/j.yexcr.2005.10.024Gorji Ali, Ghadiri Maryam Khaleghi (2002): History of headache in medieval Persian medicine. The Lancet Neurology, 1, 510-515  https://doi.org/10.1016/S1474-4422(02)00226-0 Grotenhermen F (2006): Cannabinoids and the endocannabinoid system. Cannabinoids 1, 10–14. Grotenhermen F, Muller-Vahl K (2012): The therapeutic potential of cannabis and cannabinoids. Deutsches Arzteblatt International 109, 495–501.Guzmán Manuel (2003): Cannabinoids: potential anticancer agents. Nature Reviews Cancer, 3, 745-755  https://doi.org/10.1038/nrc1188Han Sangdon, Thatte Jayant, Buzard Daniel J., Jones Robert M. (2013): Therapeutic Utility of Cannabinoid Receptor Type 2 (CB ₂ ) Selective Agonists. Journal of Medicinal Chemistry, 56, 8224-8256  https://doi.org/10.1021/jm4005626Hanus L., Breuer A., Tchilibon S., Shiloah S., Goldenberg D., Horowitz M., Pertwee R. G., Ross R. A., Mechoulam R., Fride E. (1999): HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proceedings of the National Academy of Sciences, 96, 14228-14233  https://doi.org/10.1073/pnas.96.25.14228Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D. E., Kustanovich I., Mechoulam R. (2001): 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences, 98, 3662-3665  https://doi.org/10.1073/pnas.061029898Hayakawa Kazuhide, Mishima Kenichi, Fujiwara Michihiro (2010): Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke. Pharmaceuticals, 3, 2197-2212  https://doi.org/10.3390/ph3072197Heifets Boris D., Castillo Pablo E. (2009): Endocannabinoid Signaling and Long-Term Synaptic Plasticity. Annual Review of Physiology, 71, 283-306  https://doi.org/10.1146/annurev.physiol.010908.163149Hildebrandt Audrey L., Kelly-Sullivan Dawn M., Black Shawn C. (2003): Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. European Journal of Pharmacology, 462, 125-132  https://doi.org/10.1016/S0014-2999(03)01343-8Hill Andrew J., Williams Claire M., Whalley Benjamin J., Stephens Gary J. (2012): Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics, 133, 79-97  https://doi.org/10.1016/j.pharmthera.2011.09.002Izzo Angelo A., Borrelli Francesca, Capasso Raffaele, Di Marzo Vincenzo, Mechoulam Raphael (2009): Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences, 30, 515-527  https://doi.org/10.1016/j.tips.2009.07.006Jan Tong-Rong, Farraj Aimen K, Harkema Jack R, Kaminski Norbert E (2003): Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice ☆. Toxicology and Applied Pharmacology, 188, 24-35  https://doi.org/10.1016/S0041-008X(03)00010-3 Jones RT (2002): Cardiovascular system effects of marijuana. The Journal of Clinical Pharmacology 42, 58S–63S.Kalant Harold (2001): Medicinal Use of Cannabis: History and Current Status. Pain Research and Management, 6, 80-91  https://doi.org/10.1155/2001/469629Karst Matthias, Wippermann Sonja, Ahrens Jörg (2010): Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity. Drugs, 70, 2409-2438  https://doi.org/10.2165/11585260-000000000-00000M. Keppel Hesselink Jan (2012): New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide. The Open Pain Journal, 5, 12-23  https://doi.org/10.2174/1876386301205010012Kluger Benzi, Triolo Piera, Jones Wallace, Jankovic Joseph (2015): The therapeutic potential of cannabinoids for movement disorders. Movement Disorders, 30, 313-327  https://doi.org/10.1002/mds.26142Kucerova Jana, Tabiova Katarina, Drago Filippo, Micale Vincenzo (2014): Therapeutic Potential of Cannabinoids in Schizophrenia. Recent Patents on CNS Drug Discovery, 9, 13-25  https://doi.org/10.2174/1574889809666140307115532 Landa L, Slais K, Machalova A, Sulcova A (2014a): The effect of cannabinoid CB1 receptor agonist arachidonylcyclopropylamide (ACPA) on behavioural sensitisation to methamphetamine in mice. Veterinarni Medicina 59, 88–94. Landa L, Slais K, Machalova A, Sulcova A (2014b): Interaction of CB1 receptor agonist arachidonylcyclopropylamide with behavioural sensitisation to morphine in mice. Veterinarni Medicina 59, 307–314.Lax Pedro, Esquiva Gema, Altavilla Cesare, Cuenca Nicolás (2014): Neuroprotective effects of the cannabinoid agonist HU210 on retinal degeneration. Experimental Eye Research, 120, 175-185  https://doi.org/10.1016/j.exer.2014.01.019Looney Andrea (2010): Oncology Pain in Veterinary Patients. Topics in Companion Animal Medicine, 25, 32-44  https://doi.org/10.1053/j.tcam.2009.10.008LoVerme Jesse, La Rana Giovanna, Russo Roberto, Calignano Antonio, Piomelli Daniele (2005): The search for the palmitoylethanolamide receptor. Life Sciences, 77, 1685-1698  https://doi.org/10.1016/j.lfs.2005.05.012Luongo Livio, Guida Francesca, Boccella Serena, Bellini Giulia, Gatta Luisa, Rossi Francesca, de Novellis Vito, Maione Sabatino (2013): Palmitoylethanolamide Reduces Formalin-Induced Neuropathic-Like Behaviour Through Spinal Glial/Microglial Phenotypical Changes in Mice. CNS & Neurological Disorders - Drug Targets, 12, 45-54  https://doi.org/10.2174/1871527311312010009Lynch Mary E., Campbell Fiona (2011): Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology, 72, 735-744  https://doi.org/10.1111/j.1365-2125.2011.03970.xLynch M. E., Ware Mark A. (2015): Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials. Journal of Neuroimmune Pharmacology, 10, 293-301  https://doi.org/10.1007/s11481-015-9600-6Lynch Mary E., Cesar-Rittenberg Paula, Hohmann Andrea G. (2014): A Double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension Using an Oral Mucosal Cannabinoid Extract for Treatment of Chemotherapy-Induced Neuropathic Pain. Journal of Pain and Symptom Management, 47, 166-173  https://doi.org/10.1016/j.jpainsymman.2013.02.018Maione Sabatino, Costa Barbara, Di Marzo Vincenzo (2013): Endocannabinoids: A unique opportunity to develop multitarget analgesics. PAIN®, 154, S87-S93  https://doi.org/10.1016/j.pain.2013.03.023Massi Paola, Solinas Marta, Cinquina Valentina, Parolaro Daniela (2013): Cannabidiol as potential anticancer drug. British Journal of Clinical Pharmacology, 75, 303-312  https://doi.org/10.1111/j.1365-2125.2012.04298.xMatsuda Lisa A., Lolait Stephen J., Brownstein Michael J., Young Alice C., Bonner Tom I. (1990): Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564  https://doi.org/10.1038/346561a0 McCarthy LE, Borison HL (1981): Antiemetic activity of N-methyllevonantradol and nabilone in cisplatin-treated cats. Journal of Clinical Pharmacology 21, 30S–37S.Mechoulam Raphael (2005): Plant cannabinoids: a neglected pharmacological treasure trove. British Journal of Pharmacology, 146, 913-915  https://doi.org/10.1038/sj.bjp.0706415Mechoulam Raphael, Fride Ester, Di Marzo Vincenzo (1998): Endocannabinoids. European Journal of Pharmacology, 359, 1-18  https://doi.org/10.1016/S0014-2999(98)00649-9Mechoulam Raphael, Hanuš Lumír O., Pertwee Roger, Howlett Allyn C. (): Early phytocannabinoid chemistry to endocannabinoids and beyond. Nature Reviews Neuroscience, 15, 757-764  https://doi.org/10.1038/nrn3811Mendizábal V E, Adler-Graschinsky E (2007): Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. British Journal of Pharmacology, 151, 427-440  https://doi.org/10.1038/sj.bjp.0707261Meola Stacy D., Tearney Caitlin C., Haas Sharlee A., Hackett Timothy B., Mazzaferro Elisa M. (2012): Evaluation of trends in marijuana toxicosis in dogs living in a state with legalized medical marijuana: 125 dogs (2005-2010). Journal of Veterinary Emergency and Critical Care, 22, 690-696  https://doi.org/10.1111/j.1476-4431.2012.00818.xMiller L. K., Devi L. A. (): The Highs and Lows of Cannabinoid Receptor Expression in Disease: Mechanisms and Their Therapeutic Implications. Pharmacological Reviews, 63, 461-470  https://doi.org/10.1124/pr.110.003491Muccioli Giulio G. (2010): Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discovery Today, 15, 474-483  https://doi.org/10.1016/j.drudis.2010.03.007Mukhopadhyay Partha, Bátkai Sándor, Rajesh Mohanraj, Czifra Nora, Harvey-White Judith, Haskó György, Zsengeller Zsuzsanna, Gerard Norma P., Liaudet Lucas, Kunos George, Pacher Pál (2007): Pharmacological Inhibition of CB1 Cannabinoid Receptor Protects Against Doxorubicin-Induced Cardiotoxicity. Journal of the American College of Cardiology, 50, 528-536  https://doi.org/10.1016/j.jacc.2007.03.057Munro Sean, Thomas Kerrie L., Abu-Shaar Muna (1993): Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65  https://doi.org/10.1038/365061a0Nagarkatti Prakash, Pandey Rupal, Rieder Sadiye Amcaoglu, Hegde Venkatesh L, Nagarkatti Mitzi (2009): Cannabinoids as novel anti-inflammatory drugs. Future Medicinal Chemistry, 1, 1333-1349  https://doi.org/10.4155/fmc.09.93 Nolen RS (2013): With pet owners already using the drug as medicine, veterinarians need to join the debate. Journal of the American Veterinary Medical Association 242, 1604–1609.Pacher P. (2006): The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews, 58, 389-462  https://doi.org/10.1124/pr.58.3.2Parker Linda A., Kwiatkowska Magdalena, Burton Page, Mechoulam Raphael (2004): Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology, 171, 156-161  https://doi.org/10.1007/s00213-003-1571-2Pascual David, Goicoechea Carlos, Suardíaz Margarita, Martín María Isabel (2005): A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain, 118, 23-34  https://doi.org/10.1016/j.pain.2005.07.008Pate David W., Järvinen Kristiina, Urtti Arto, Mahadevan Vaidyanath, Järvinen Tomi (1998): Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sciences, 63, 2181-2188  https://doi.org/10.1016/S0024-3205(98)00499-8Pertwee Roger G. (1997): Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology & Therapeutics, 74, 129-180  https://doi.org/10.1016/S0163-7258(97)82001-3Pertwee Roger G. (2005): The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. The AAPS Journal, 7, E625-E654  https://doi.org/10.1208/aapsj070364Pertwee Roger G (2009): Emerging strategies for exploiting cannabinoid receptor agonists as medicines. British Journal of Pharmacology, 156, 397-411  https://doi.org/10.1111/j.1476-5381.2008.00048.xPertwee Roger G. (2014): Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proceedings of the Nutrition Society, 73, 96-105  https://doi.org/10.1017/S0029665113003649Porcella Anna, Maxia Chiara, Gessa Gian Luigi, Pani Luca (2001): The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. European Journal of Neuroscience, 13, 409-412  https://doi.org/10.1046/j.0953-816X.2000.01401.xPorter A. C. (): Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor. Journal of Pharmacology and Experimental Therapeutics, 301, 1020-1024  https://doi.org/10.1124/jpet.301.3.1020 Presley BC, Jansen-Varnum SA, Logan BK (2013): Analysis of synthetic cannabinoids in botanical material: A review of analytical methods and findings. Forensic Science Review 25, 27–46.Re G., Barbero R., Miolo A., Di Marzo V. (2007): Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. The Veterinary Journal, 173, 21-30  https://doi.org/10.1016/j.tvjl.2005.10.003ROBSON P. (): Therapeutic aspects of cannabis and cannabinoids. The British Journal of Psychiatry, 178, 107-115  https://doi.org/10.1192/bjp.178.2.107Rog D. J., Nurmikko T. J., Friede T., Young C. A. (): Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 65, 812-819  https://doi.org/10.1212/01.wnl.0000176753.45410.8bRoss Ruth A (2003): Anandamide and vanilloid TRPV1 receptors. British Journal of Pharmacology, 140, 790-801  https://doi.org/10.1038/sj.bjp.0705467Russo Ethan (2008): Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management, Volume 4, 245-259  https://doi.org/10.2147/TCRM.S1928Sarfaraz S., Adhami V. M., Syed D. N., Afaq F., Mukhtar H. (2008): Cannabinoids for Cancer Treatment: Progress and Promise. Cancer Research, 68, 339-342  https://doi.org/10.1158/0008-5472.CAN-07-2785Scarampella F., Abramo F., Noli C. (2001): Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Veterinary Dermatology, 12, 29-39  https://doi.org/10.1046/j.1365-3164.2001.00214.xScheen André J., Paquot Nicolas (2009): Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Practice & Research Clinical Endocrinology & Metabolism, 23, 103-116  https://doi.org/10.1016/j.beem.2008.09.001Serpell M., Ratcliffe S., Hovorka J., Schofield M., Taylor L., Lauder H., Ehler E. (2014): A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain, 18, 999-1012  https://doi.org/10.1002/j.1532-2149.2013.00445.xSlais K., Landa L., Sulcova A. (2003): P.5.023 The effects of cannabinoid CB1 receptor antagonist AM 251 on locomotor/exploratory behaviour and body weight in mice. European Neuropsychopharmacology, 13, S417-  https://doi.org/10.1016/S0924-977X(03)92272-3Slavic Svetlana, Lauer Dilyara, Sommerfeld Manuela, Kemnitz Ulrich Rudolf, Grzesiak Aleksandra, Trappiel Manuela, Thöne-Reineke Christa, Baulmann Johannes, Paulis Ludovit, Kappert Kai, Kintscher Ulrich, Unger Thomas, Kaschina Elena (2013): Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. Journal of Molecular Medicine, 91, 811-823  https://doi.org/10.1007/s00109-013-1034-0 Song ZH, Slowey CA (2000): Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. Journal of Pharmacology and Experimental Therapeutics 292, 136–139. Stanley CP, Hind WH, O’Sullivan SE (2013): Is the cardiovascular system a therapeutic target for cannabidiol? British Journal of Clinical Pharmacology 75, 313–322.Steffens Sabine, Pacher Pál (2012): Targeting cannabinoid receptor CB2 in cardiovascular disorders: promises and controversies. British Journal of Pharmacology, 167, 313-323  https://doi.org/10.1111/j.1476-5381.2012.02042.xSteffens Sabine, Veillard Niels R., Arnaud Claire, Pelli Graziano, Burger Fabienne, Staub Christian, Zimmer Andreas, Frossard Jean-Louis, Mach François (2005): Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature, 434, 782-786  https://doi.org/10.1038/nature03389SVIZENSKA I, DUBOVY P, SULCOVA A (2008): Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures — A short review. Pharmacology Biochemistry and Behavior, 90, 501-511  https://doi.org/10.1016/j.pbb.2008.05.010Tallett Amy J., Blundell John E., Rodgers John R. (2007): Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation. Behavioural Pharmacology, 18, 591-600  https://doi.org/10.1097/FBP.0b013e3282eff0a9 Unschuld PU (1986): Medicine in China. A History of Pharmaceutics. University of California Press, Berkeley and Los Angele. 167 pp.Van Sickle Marja D., Oland Lorraine D., Mackie Ken, Davison Joseph S., Sharkey Keith A. (): Δ ⁹ -Tetrahydrocannabinol selectively acts on CB ₁ receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. American Journal of Physiology - Gastrointestinal and Liver Physiology, 285, G566-G576  https://doi.org/10.1152/ajpgi.00113.2003Van Sickle M. D. (2005): Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors. Science, 310, 329-332  https://doi.org/10.1126/science.1115740Velasco Guillermo, Sánchez Cristina, Guzmán Manuel (): Towards the use of cannabinoids as antitumour agents. Nature Reviews Cancer, 12, 436-444  https://doi.org/10.1038/nrc3247Weiss L., Zeira M., Reich S., Har-Noy M., Mechoulam R., Slavin S., Gallily R. (2006): Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity, 39, 143-151  https://doi.org/10.1080/08916930500356674Weiss Lola, Zeira Michael, Reich Shoshana, Slavin Shimon, Raz Itamar, Mechoulam Raphael, Gallily Ruth (2008): Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology, 54, 244-249  https://doi.org/10.1016/j.neuropharm.2007.06.029Xiong W., Cui T., Cheng K., Yang F., Chen S.-R., Willenbring D., Guan Y., Pan H.-L., Ren K., Xu Y., Zhang L. (): Cannabinoids suppress inflammatory and neuropathic pain by targeting  3 glycine receptors. Journal of Experimental Medicine, 209, 1121-1134  https://doi.org/10.1084/jem.20120242Zuardi Antonio Waldo (2006): History of cannabis as a medicine: a review. Revista Brasileira de Psiquiatria, 28, 153-157  https://doi.org/10.1590/S1516-44462006000200015 Zubrzycki M, Liebold A, Janecka A, Zubrzycka M (2014): A new face of endocannabinoids in pharmacotherapy. Part I: Protective role of endocannabinoids in hypertension and myocardial infarction. Journal of Physiology and Pharmacology 65, 171–181.